Dr. Reddy’s Laboratories Receives USFDA Observations Post-Inspection

Dr Reddy’s Laboratories ( (RDY) ) has provided an announcement.

On September 12, 2025, Dr. Reddy’s Laboratories announced that the USFDA completed a Pre-Approval Inspection at their biologics manufacturing facility in Bachupally, Hyderabad. The inspection, which took place from September 4 to September 12, 2025, resulted in a Form 483 with five observations. The company has committed to addressing these observations within the stipulated timeline, which is crucial for maintaining compliance and advancing their market position in the biologics sector.

The most recent analyst rating on (RDY) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories exhibits strong financial health and strategic growth initiatives, which are offset by challenges in the U.S. generics market and declining gross profit margins. The technical analysis suggests stability, while the valuation is fair. The earnings call provided a mixed outlook, balancing growth with market challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. It operates in the healthcare industry, focusing on the development, manufacture, and marketing of a wide range of pharmaceuticals, including generic medications, active pharmaceutical ingredients, and biologics. The company is publicly traded on multiple stock exchanges, including the National Stock Exchange of India and the New York Stock Exchange.

Average Trading Volume: 1,256,617

Technical Sentiment Signal: Strong Buy

Current Market Cap: $12.44B

Learn more about RDY stock on TipRanks’ Stock Analysis page.